3-苯基丙烯酸7,8-二去氢-4,5a-环氧-3-甲氧基-17-甲基-6-氧代吗喃-14-基酯 | 751-01-9

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 中文名称: 3-苯基丙烯酸7,8-二去氢-4,5a-环氧-3-甲氧基-17-甲基-6-氧代吗喃-14-基酯
• 英文名称: 14-Cinnamoyloxycodeinone
• 英文别名: [(4R,4aS,7aR,12bS)-9-methoxy-3-methyl-7-oxo-2,4,7a,13-tetrahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-yl] (E)-3-phenylprop-2-enoate
• CAS: 751-01-9
• 化学式: C₂₇H₂₅NO₅
• 分子量: 443.5
• InChiKey: BWZTYCFJIMYOHI-JKGZCERPSA-N

物化性质

• 沸点：
  553.79°C (rough estimate)
• 密度：
  1.2391 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  65.1
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE
  申请人：Waterville Valley Technologies, Inc.

  公开号：US20160326182A1

  公开（公告）日：2016-11-10

  Abuse-resistant opioid compounds, drug delivery systems, pharmaceutical compositions comprising an opioid covalently bound to a chemical moiety are provided. Methods of delivering an active ingredient to a subject and methods of preventing opioid abuse are also provided.

  提供了耐滥用的阿片类化合物、药物输送系统、含有阿片类药物与化学基团共价结合的制药组合物。还提供了将活性成分输送给受试者的方法以及预防阿片类药物滥用的方法。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN AND DEPENDANCE DISORDERS<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE LA DOULEUR ET DE TROUBLES DE LA DÉPENDANCE
  申请人：RIPPLE THERAPEUTICS CORP

  公开号：WO2021024039A1

  公开（公告）日：2021-02-11

  Provided herein are (e.g., controlled release) compositions for the treatment of acute or chronic diseases or disorders. Described herein are processable opioid conjugates. Also described herein are compositions and methods for the treatment of central nervous system (CNS) diseases or disorders including chronic pain (e.g., cancer pain), acute pain, opioid addiction, alcohol addiction, alcohol dependence, opioid-induced constipation, and narcotic depression. Said compositions and methods comprise opioid agonists and/or opioid antagonists, which demonstrate CNS activity and/or other desirable activities. Injection of said compositions subcutaneously or intraspinally provides therapeutic benefit to individuals suffering from CNS diseases or disorders

  本文提供了用于治疗急性或慢性疾病或障碍的（例如，控释）组合物。本文描述了可加工的阿片类结合物。本文还描述了用于治疗中枢神经系统（CNS）疾病或障碍的组合物和方法，包括慢性疼痛（例如，癌症疼痛）、急性疼痛、阿片类成瘾、酒精成瘾、酒精依赖、阿片类引起的便秘和麻醉性抑郁症。所述组合物和方法包括表现出CNS活性和/或其他理想活性的阿片类激动剂和/或阿片类拮抗剂。将所述组合物皮下或脊髓内注射可为患有中枢神经系统疾病或障碍的个体提供治疗益处。
• Methods and compositions for preventing opioid abuse
  申请人：Waterville Valley Technologies, Inc.

  公开号：US10226456B2

  公开（公告）日：2019-03-12

  Abuse-resistant opioid compounds, drug delivery systems, pharmaceutical compositions comprising an opioid covalently bound to a chemical moiety are provided. Methods of delivering an active ingredient to a subject and methods of preventing opioid abuse are also provided.

  提供了抗滥用阿片类化合物、给药系统、药物组合物，其中包含与化学分子共价结合的阿片类药物。此外，还提供了向受试者输送活性成分的方法和防止滥用阿片类药物的方法。
• Compositions for drug administration
  申请人：Aegis Therapeutics, LLC

  公开号：US10576156B2

  公开（公告）日：2020-03-03

  The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.

  本发明提供了提高治疗剂在受试者体内的生物利用度的组合物和方法。组合物包括至少一种烷基糖苷和至少一种治疗剂，其中烷基糖苷的烷基链长约为 10 至 16 个碳原子。
• Pharmaceutical formulation
  申请人：Klaria Pharma Holding AB

  公开号：US11219600B2

  公开（公告）日：2022-01-11

  The present invention relates to a film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and an antagonist of an opioid receptor, an inverse agonist of an opioid receptor, or a prodrug thereof. The present invention further relates to methods for manufacturing such a film, and the use of such a film in the treatment of a human patient, in particular the use of such a film in the treatment of the effects of acute opioid overdose, or the use of such a film in reducing the risk of opioid abuse.

  本发明涉及一种薄膜，该薄膜包含单价阳离子的藻酸盐或含有至少一种单价阳离子的藻酸盐的藻酸盐混合物，以及阿片受体的拮抗剂、阿片受体的反向激动剂或其原药。本发明进一步涉及制造这种薄膜的方法，以及将这种薄膜用于治疗人类患者，特别是将这种薄膜用于治疗阿片类药物急性过量的影响，或将这种薄膜用于降低阿片类药物滥用的风险。